oral+semaglutide+approval FDA approves first-ever oral GLP-1RA for obesity and chronic weight management. Meet Wegovy (semaglutide) tablets. https://www.prnewswire.com/news-releases/fda-approves-novo-nordisks-wegovy-pill-the-first-and-only- oral-glp-1-for-weight-loss-in-adults FDA Approves Oral Semaglutide as

In skin research, glutathione acts on radiance and depigmentation (tyrosinase inhibition, antioxidation)

I take 2 tablets a day

The approval represented a significant milestone as Wegovy became the first FDA-approved treatment for chronic weight management in adults since 2014, strengthening the adoption of long-acting GLP-1 analogues in obesity care In August 2021, results from the STEP 1 clinical trial of once-weekly semaglutide 2.4 mg were published in the New England Journal of Medicine, showing substantial weight reduction in adults with overweight or obesity without diabetes

GLP-1 receptor agonism, while primarily targeting metabolic pathways, may influence neurological function through direct effects on peripheral nerve tissue